Almirall meeting invitation for Eklira Genuair: PMCPA found it was clearly promotional (no breach)

📅 2012 | 🖉 Dr Anzal Qurbain
πŸ“Š

Key facts

Case numberAUTH/2584/3/13
ComplainantClinical pharmacist
CompanyAlmirall
Material / activityInvitation to a meeting (regional launch meeting)
MedicineEklira Genuair (aclidinium bromide inhalation powder)
Therapy areaCOPD
Main issueWhether the invitation blurred education vs promotion / disguised promotion; whether Clause 18.4 applied
Clauses consideredClause 12.1 and Clause 18.4
DecisionNo breach of the Code
Complaint received7 March 2013
Case completed16 April 2013
Applicable Code year2012

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) β€” ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors β€” instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough β€” coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe β€” from Β£299/yr
πŸ“‹

What happened

  • A clinical pharmacist complained about a four-page invitation to a meeting from Almirall, received via a colleague.
  • The front page was headed β€œEklira Genuair” with the non-proprietary name (aclidinium bromide inhalation powder) and the line β€œCOPD Management Guidelines”.
  • Page 2 gave a brief overview of the meeting, one speaker and the company; page 3 had agenda/date/time/venue; page 4 contained prescribing information for Eklira Genuair.
  • The complainant alleged the invitation looked educational (COPD guidelines) but prominently displayed the product name and prescribing information, potentially blurring the boundary between education and promotion.
  • The complaint was considered under Clause 12.1 and Clause 18.4.
  • Almirall said these were regional launch meetings for a newly launched respiratory product and that branding + prescribing information + sponsorship statement were included to make sponsorship and promotional intent unambiguous.
βš–οΈ

Outcome

  • The Panel ruled the invitation and meeting were promotional and that this was clear from the outset.
  • No breach of Clause 12.1.
  • No breach of Clause 18.4 (because it applies to non-promotional medical and educational goods and services, not promotional invitations).
  • Overall: No breach of the Code.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
Β£249/year
Annual β€” save Β£99
or
Β£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training